HOWL – werewolf therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Werewolf Therapeutics (NASDAQ:HOWL) had its price target lowered by analysts at Bank of America Corporation from $8.00 to $7.00. They now have a "buy" rating on the stock.
Werewolf Therapeutics (NASDAQ:HOWL) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Form 4 Werewolf Therapeutics, For: Dec 02 Filed by: MPM BioVentures 2014 LLC
Form 4 Werewolf Therapeutics, For: Dec 02 Filed by: EVNIN LUKE
Form 4 Werewolf Therapeutics, For: Dec 02 Filed by: Oncology Impact Fund (Cayman) Management L.P.
Form SCHEDULE 13D/A Werewolf Therapeutics, Filed by: MPM BioVentures 2014, L.P.
Form 144 Werewolf Therapeutics, Filed by: MPM BioVentures 2014 (B), L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.